Endocrine oncology

Exploring the Molecular Features and Clinicopathological Correlations of Diffuse Sclerosing Papillary Thyroid Carcinoma

Clin Endocrinol (Oxf)Published Retrospective cohort study

Authors' conclusion

DSV-PTC demonstrates substantial molecular heterogeneity. RET fusions are linked to more aggressive behaviour, and paediatric cases often show extensive locoregional spread. Coexisting NTRK and TERT alterations may signal high-risk progression, highlighting the value of molecular stratification in management.

Study context

Population
Diffuse sclerosing variant of PTC (diffuse sclerosing variant of papillary thyroid carcinoma (DSV-PTC)); 8 paediatric and 43 adult cases
Participants
51 participants
Exposure
RET fusion-positive vs BRAF-mutated DSV-PTC
Outcome
Molecular alterations

Main finding

As reported in the abstract

BRAF mutation
39.2%
RET fusions
25.5%
CCDC6-RET
23.5%
NCOA4-RET
2.0%
ETV6-NTRK3 fusion
5.9%
TERT promoter mutations
2.0%

Observational data: associations, not effects.

Further findings

OutcomeP value
Clinicopathological features, RET fusion vs BRAF-mutatedRET fusion vs BRAF-mutated · significantly larger primary tumours with RET fusionP = 0.016
Clinicopathological features, RET fusion vs BRAF-mutatedRET fusion vs BRAF-mutated · larger metastatic nodes with RET fusionP = 0.009
Clinicopathological features, RET fusion vs BRAF-mutatedRET fusion vs BRAF-mutated · higher T stages with RET fusionP = 0.046

Paediatric vs adult cases

Paediatric patients had higher rates of lateral neck metastasis and extrathyroidal extension but fewer BRAF mutations

Recurrence

Overall recurrence rate
15.7%
Coexisting ETV6-NTRK3 fusion and TERT mutation progressed to ATC and died of disease
1 patient
Earlier recurrence in RET fusion cases

Original publication

Exploring the Molecular Features and Clinicopathological Correlations of Diffuse Sclerosing Papillary Thyroid Carcinoma. Clin Endocrinol (Oxf). Published 11 August 2025. doi:10.1111/cen.70013

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.